WO2001062266A3 - Inhibition de la degenerescence des cellules beta - Google Patents
Inhibition de la degenerescence des cellules beta Download PDFInfo
- Publication number
- WO2001062266A3 WO2001062266A3 PCT/DK2001/000115 DK0100115W WO0162266A3 WO 2001062266 A3 WO2001062266 A3 WO 2001062266A3 DK 0100115 W DK0100115 W DK 0100115W WO 0162266 A3 WO0162266 A3 WO 0162266A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- dpp
- relates
- inhibitors
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 102100023915 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001561331A JP2003523396A (ja) | 2000-02-25 | 2001-02-20 | ベータ細胞変性の抑制 |
AU2001233622A AU2001233622A1 (en) | 2000-02-25 | 2001-02-20 | Inhibition of beta cell degeneration |
EP01905634A EP1259246A2 (fr) | 2000-02-25 | 2001-02-20 | Inhibition de la degenerescence des cellules beta |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000295 | 2000-02-25 | ||
DKPA200000295 | 2000-02-25 | ||
DKPA200000983 | 2000-06-23 | ||
DKPA200000983 | 2000-06-23 | ||
DKPCT/DK01/00045 | 2001-01-22 | ||
PCT/DK2001/000045 WO2001055105A1 (fr) | 2000-01-24 | 2001-01-22 | 2-cyanopyroles et -pyrrolines a substitution n inhibant l'enzyme dpp-iv |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001062266A2 WO2001062266A2 (fr) | 2001-08-30 |
WO2001062266A3 true WO2001062266A3 (fr) | 2002-05-02 |
Family
ID=27222185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2001/000115 WO2001062266A2 (fr) | 2000-02-25 | 2001-02-20 | Inhibition de la degenerescence des cellules beta |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1259246A2 (fr) |
JP (1) | JP2003523396A (fr) |
AU (1) | AU2001233622A1 (fr) |
WO (1) | WO2001062266A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19926233C1 (de) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
KR20080067009A (ko) | 2000-03-31 | 2008-07-17 | 프로시디온 리미티드 | 디펩티딜 펩티다제 ⅳ 효소 활성 억제제를 포함하는약제학적 조성물 |
US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
WO2003002531A2 (fr) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
DE60223920T2 (de) | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
WO2003057144A2 (fr) * | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Changement d'inhibiteurs de la dipeptidyl peptidase iv |
ES2278944T3 (es) | 2002-02-28 | 2007-08-16 | Prosidion Ltd. | Inhibidores de dpiv basados en glutaminilo. |
JPWO2004007446A1 (ja) * | 2002-07-10 | 2005-11-10 | アステラス製薬株式会社 | 新規なアゼチジン誘導体又はその塩 |
US20060039974A1 (en) | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
DE202004021723U1 (de) | 2003-05-05 | 2010-07-15 | Probiodrug Ag | Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen |
MXPA05013734A (es) | 2003-06-20 | 2006-03-08 | Hoffmann La Roche | Hexahidropiroisoquinolinas como inhibidores de dpp-iv. |
SI1638970T1 (sl) | 2003-06-20 | 2011-03-31 | Hoffmann La Roche | Derivati pirid (2, 1-a)-izokinolina kot inhibitorji dpp-iv |
JP5707014B2 (ja) | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
JP4854511B2 (ja) * | 2004-08-26 | 2012-01-18 | 武田薬品工業株式会社 | 糖尿病治療剤 |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ATE550319T1 (de) | 2007-03-22 | 2012-04-15 | Kyorin Seiyaku Kk | Verfahren zur herstellung eines aminoacetylpyrrolidincarbonitrilderivats |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010127A1 (fr) * | 1991-11-22 | 1993-05-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procede de production d'un ester de prolineboronate |
WO1995015309A1 (fr) * | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
WO1995029691A1 (fr) * | 1994-04-28 | 1995-11-09 | Georgia Tech Research Corporation | Derives de la proline phosphonate |
WO1997040832A1 (fr) * | 1996-04-25 | 1997-11-06 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Utilisation d'effecteurs de la dipeptidyl peptidase iv pour abaisser la teneur en glucose dans le sang chez les mammiferes |
WO1998019998A2 (fr) * | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
WO1999038501A2 (fr) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Procede de regulation du metabolisme du glucose et reactifs afferents |
DE29909210U1 (de) * | 1998-05-28 | 1999-09-09 | Probiodrug Ges Fuer Arzneim | Neue Effektoren von Dipeptidylpeptidase IV |
WO1999046272A1 (fr) * | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Modulateurs de la serine peptidase |
WO1999067278A1 (fr) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Promedicaments d'inhibiteurs de la dipeptidylpeptidase iv |
WO1999067279A1 (fr) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Composes d'inhibiteurs instables de la dipeptidylpeptidase iv |
-
2001
- 2001-02-20 JP JP2001561331A patent/JP2003523396A/ja active Pending
- 2001-02-20 WO PCT/DK2001/000115 patent/WO2001062266A2/fr not_active Application Discontinuation
- 2001-02-20 AU AU2001233622A patent/AU2001233622A1/en not_active Abandoned
- 2001-02-20 EP EP01905634A patent/EP1259246A2/fr not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010127A1 (fr) * | 1991-11-22 | 1993-05-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Procede de production d'un ester de prolineboronate |
WO1995015309A1 (fr) * | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
WO1995029691A1 (fr) * | 1994-04-28 | 1995-11-09 | Georgia Tech Research Corporation | Derives de la proline phosphonate |
WO1997040832A1 (fr) * | 1996-04-25 | 1997-11-06 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Utilisation d'effecteurs de la dipeptidyl peptidase iv pour abaisser la teneur en glucose dans le sang chez les mammiferes |
WO1998019998A2 (fr) * | 1996-11-07 | 1998-05-14 | Novartis Ag | 2-cyanopyrrolidines a substitution n |
WO1999038501A2 (fr) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Procede de regulation du metabolisme du glucose et reactifs afferents |
WO1999046272A1 (fr) * | 1998-03-09 | 1999-09-16 | Fondatech Benelux N.V. | Modulateurs de la serine peptidase |
DE29909210U1 (de) * | 1998-05-28 | 1999-09-09 | Probiodrug Ges Fuer Arzneim | Neue Effektoren von Dipeptidylpeptidase IV |
DE29909208U1 (de) * | 1998-05-28 | 1999-09-09 | Probiodrug Ges Fuer Arzneim | Neue Effektoren von Dipeptidylpeptidase IV |
DE29909211U1 (de) * | 1998-05-28 | 1999-09-23 | Probiodrug Ges Fuer Arzneim | Neue Effektoren von Dipeptidylpeptidase IV |
WO1999067278A1 (fr) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Promedicaments d'inhibiteurs de la dipeptidylpeptidase iv |
WO1999067279A1 (fr) * | 1998-06-24 | 1999-12-29 | Probiodrug Gesellschaft für Arzneimittelforschung mbH | Composes d'inhibiteurs instables de la dipeptidylpeptidase iv |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2001062266A2 (fr) | 2001-08-30 |
JP2003523396A (ja) | 2003-08-05 |
AU2001233622A1 (en) | 2001-09-03 |
EP1259246A2 (fr) | 2002-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001062266A3 (fr) | Inhibition de la degenerescence des cellules beta | |
WO2002022559A3 (fr) | Derives des acides hexenoique et hexynoique 2-amino-2-alkyl-4 inhibiteurs de la synthase de l'oxyde nitrique | |
AU2687301A (en) | Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes | |
WO2002002560A3 (en) | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) | |
AU2002327430A1 (en) | Methods for treating diabetes and other blood sugar disorders | |
HK1042496B (zh) | 新的果糖1,6-二磷酸酶的雜芳族抑制劑 | |
WO2003065994A3 (fr) | Implants de pontage schwannien et inhibiteurs de phosphodiesterase pour stimuler la regeneration des nerfs du systeme nerveux central | |
WO2001066553A3 (fr) | Nouveaux inhibiteurs de la fructose-1,6-biophosphatase, a base d'aryle | |
AU2866995A (en) | Protein kinase c inhibitors | |
WO2004098634A3 (fr) | Proteine arginine n-methyltransferase 2 (prmt-2) | |
AU2003272877A1 (en) | Electrode for fuel cell, fuel cell including the electrode and process for producing the same | |
AU2001253519A1 (en) | Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors | |
MXPA03002207A (es) | Derivados de acido 2-amino-2-alquil-5-heptenoico y -heptinoico utiles como inhibidores de la oxido nitrico sintasa. | |
EP1247857A3 (fr) | Procédé d'hydrotraitement/extraction doux pour la préparation d'un combustible à teneur en soufre réduite pour les piles à combustibles | |
WO2002004409A3 (fr) | Agents neuroprotecteurs à base d'analogues de tétrahydrobenzothiazole | |
AU2525301A (en) | Genus leontopodium plant extract and compositions containing same | |
AU2001255393A1 (en) | Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors | |
AU2003256483A1 (en) | Methods of electrochemically treating semiconductor substrates, and methods of forming capacitor constructions | |
WO2002056876A3 (fr) | Traitement pour le ronflement | |
WO2001091586A3 (fr) | Compositions de konjac mannan et de ginseng, procedes et utilisations | |
WO2002058488A3 (fr) | Composition contenant de la creatine et du phosphore | |
WO1999063979A3 (fr) | Inhibition de l'activite de δ-9-desaturase au moyen de saponines | |
AU2002350718A1 (en) | Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof | |
EP0358536A3 (fr) | Inhibiteurs de la S'-adénosylméthionedécarboxylase | |
AU2003302574A1 (en) | Method of extract composition control in peat extraction, peat extract, and use of peat extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001905634 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 561331 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001905634 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001905634 Country of ref document: EP |